p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sections
- 1 December 1992
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 168 (4), 377-381
- https://doi.org/10.1002/path.1711680407
Abstract
The distinction between reactive mesothelium and mesothelioma in pleural biopsy specimens is notoriously difficult, and conventional immunohistochemical markers have provided no relief. The object of this study was to examine the frequency of immunohistochemically detectable p53 overcxpression in routinely processed, paraffin-embedded tissue from pleural mesotheliomas and from pleura showing reactive mesothelial hyperplasia, using a polyclonal antibody to formalin-resistant p53 epitopes, and to consider the diagnostic utility of this antibody in the distinction between mesothelioma and reactive mesothelium in pleural biopsy specimens. Immunostaining was enhanced by pepsin predigestion prior to the application of the primary antibody. Positivity occurred in 10/16 epithelial mesotheliomas, 9/19 biphasic mesotheliomas, 2/12 sarcomatous mesotheliomas but in none of 20 reactive pleura. Immunostaining was particularly intense in some of the biopsy specimens, which may be due to the rapidity with which these small pieces of tissue were fixed. In conclusion, this study suggests that p53 immunostaining can help to distinguish epithelial or biphasic mesothelioma from reactive mesothelial hyperplasia in formalin-fixed, paraffin-embedded pleural biopsy specimens.Keywords
This publication has 12 references indexed in Scilit:
- P53 in tumour pathology: Can we trust immunocytochemistry?The Journal of Pathology, 1992
- The histology and immunohistochemistry of small cell mesotheliomaHistopathology, 1992
- p53 immunostaining as a marker of malignant disease in diagnostic cytopathologyThe Lancet, 1991
- Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: An immunohistochemical approach using a panel of monoclonal antibodiesJournal of Surgical Oncology, 1990
- Mutant p53—the commonest genetic abnormality in human cancer?The Journal of Pathology, 1990
- Role of asbestos and other fibres in the development of diffuse malignant mesothelioma.Thorax, 1990
- Increased expression of mutant forms of p53 oncogene in primary lung cancerThe Lancet, 1990
- Expression of the nuclear oncogene p53 in colon tumoursThe Journal of Pathology, 1989
- Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma.Thorax, 1985
- Diagnosis of pleural malignant mesothelioma in life—a practical approachThe Journal of Pathology, 1984